Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05272475
Other study ID # IRB2022-00036
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 16, 2022
Est. completion date May 12, 2022

Study information

Verified date June 2022
Source Stony Brook University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chamomile may possess anticoagulant effects based on the presence of coumarin-like compounds within the flower. This randomized complete crossover study will investigate the impact of chamomile ingestion acutely on coagulation.


Description:

Subjects will be enrolled into two groups in a crossover fashion upon obtaining written informed consent. The two intervention groups include (1) chamomile tea intake and (2) chamomile extract intake. Subjects will consume a single preparation of chamomile tea or extract capsule, and partake in a minimum of three days washout period between interventions. Screening assays of coagulation will be obtained immediately before the ingestion of chamomile, two hours after ingestion, and four hours after ingestion over the course of a single day.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date May 12, 2022
Est. primary completion date May 12, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Able to provide informed written consent - Able to withhold use of other chamomile products (teas, lotions, supplements, extracts); will only use study-supplied chamomile products for duration of study - Able to withhold intake of solid food at least 6 hours before intake of the chamomile preparation - Able to withhold intake of clear liquids at least 2 hours before intake of the chamomile preparation Exclusion Criteria: - Past medical/family history of bleeding/thrombotic disorders (e.g. hemophilia, von-Willebrand disease) - Chronic medications known to affect hemostasis (anticoagulants, antiplatelet agents, SSRIs, herbal/complementary medicine agents) - Three or more alcoholic drinks daily - Sedentary status/ restricted mobility - Active smoker or quit smoking within one week of study period - Females who are pregnant, breast-feeding, or lactating - History of estrogen-dependent condition such as uterine fibroids, breast cancer, uterine cancer, or ovarian cancer - Scheduled surgical procedure during study period - Hospitalized patients - Underweight (BMI < 18 kg/m2) or history of malnourishment - Active symptoms of a respiratory, dermatologic, urinary, or gastrointestinal infection - Diagnosed allergy to chamomile - Severe allergy to ragweed - Physical inability to consume chamomile tea according to the study dosing schedule - Prescription usage of an anticoagulant agent such as warfarin, anti-Xa inhibitor, or other novel oral anticoagulants - ADP antagonist use, including clopidogrel, prasugrel, and ticagrelor - GPIIb/IIIa inhibitor use, including ticlopidine, eptifibatide - More than weekly NSAID use (e.g. aspirin, ibuprofen, naproxen) - Diagnosis of a bleeding-diathesis disorder - Diagnosis of a hypercoagulable state - History of elevated INR or other abnormal bleeding study (PT, aPTT, thrombin time, reptilase time, above the upper limit of normal for Stony Brook Hospital Reference Range) while not taking anticoagulants or herbal supplements listed below - Active intake of the following herbal supplements at time of study enrollment that may alter baseline coagulation function including: - Ginger - Garlic - Gingko - Ginseng - Fish oil - Black Cohosh - Feverfew - Valerian - Coenzyme Q10 - Goldenseal - St. John Wort - Active intake of chamomile extracts or teas at time of study enrollment - Inability to discontinue the aforementioned herbal supplements more than 14 days before enrollment into the study - Significant fear of needles or fainting blood draws - Actively taking cyclosporine - Patient refusal to participate in study for the allotted study period

Study Design


Intervention

Dietary Supplement:
Chamomile Tea
Chamomile tea bags consumed by subjects as described in study arms section.
Chamomile Extract Capsule
Chamomile extract capsules consumed by subjects as described in "Experimental: Chamomile Extract Capsule" study arms section.

Locations

Country Name City State
United States Stony Brook University Hospital Stony Brook New York

Sponsors (1)

Lead Sponsor Collaborator
Stony Brook University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Prothrombin Time At two hours and four hours after the intervention
Secondary Change in Activated Partial Thromboplastin Time At two hours and four hours after the intervention
Secondary Change in Thrombin Time At two hours and four hours after the intervention
Secondary Change in Reptilase Time At two hours and four hours after the intervention
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Recruiting NCT03136510 - Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban N/A
Completed NCT01588132 - Anfibatide Phase 1 Clinical Trial in Healthy Volunteers Phase 1
Recruiting NCT04488341 - Effect of Aerobic Exercises on Sex Hormones and Coagulation Factors in Postmenopausal Elderly Women N/A
Recruiting NCT04524637 - The Utility of Thromboelastography in Traumatic Brain Injury
Completed NCT03634215 - Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma
Completed NCT05152420 - Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects Phase 1
Recruiting NCT05645081 - Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke
Completed NCT04322721 - Coagulopathy on the First Postoperative Day Predicts the Long-term Survival of Traumatic Brain Injury Patients
Completed NCT03267823 - INR Comparison Testing in Cardiac Surgery
Completed NCT04490759 - QStat Pilot Reference Range Study
Completed NCT04107818 - Comparison of Viscoelastic Measurement by ROTEM® Delta and ClotPro® in Trauma Patients.
Recruiting NCT05484830 - Coagulation in Acute Aortic Dissection N/A
Recruiting NCT04111120 - Heparin Like Effect in Acute Variceal Bleeding
Completed NCT05162339 - Inflammatory Bowel Disease and Thromboembolic Events
Completed NCT03555630 - Thromboelastogram in Postdelivery Preeclamptic Patients
Completed NCT01589172 - Evaluating the Use of Thromboelastography to Diagnose Coagulopathy After Traumatic Brain Injury
Recruiting NCT04278404 - Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Completed NCT03956836 - Perioperative Coagulopathy in Patients Undergoing Cytoreductive Surgery and HIPEC Intraperitoneal Chemotherapy (HIPEC)